Australian company Telix has announced that it will supply ILLUCIX for a Phase 3 study investigating the efficacy of Bayer's PBS-listed NUBEQA (darolutamide) plus androgen deprivation therapy in hormone-sensitive prostate cancer. …
Australian company to supply Bayer with Illuccix for prostate cancer study
May 9, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News